CA Patent

CA2787844C — Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency

Assigned to Medivation Technologies LLC · Expires 2019-08-27 · 7y expired

What this patent protects

A compound having the structure set forth in Formula (I) and Formula (II) wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein Provided herein are inhibitors of poly(ADP-ribose)polymerase activity Also described herein are pharmaceutical compositions t…

USPTO Abstract

A compound having the structure set forth in Formula (I) and Formula (II) wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein Provided herein are inhibitors of poly(ADP-ribose)polymerase activity Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity

Drugs covered by this patent

Patent Metadata

Patent number
CA2787844C
Jurisdiction
CA
Classification
—
Expires
2019-08-27
Drug substance claim
No
Drug product claim
No
Assignee
Medivation Technologies LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.